retatrutide ly3437943 triple agonist glp-1 gip glucagon mechanism Beyond GLP -1: Retatrutide's triple-agonist (GLP-1, GIP, glucagon) is redefining metabolic health. Phase 2 data shows ~24% weight loss—surpassing semaglutide & tirzepatide. Evidence-based LY3437943, a novel triple glucagon,
Pay in 4 interest-free payments of $6.98 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
























